Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Mitigation strategies for ibrutinib-associated cardiac AEs in Waldenström’s macroglobulinemia

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on mitigation strategies for ibrutinib-related cardiac toxicity in patients with Waldenström’s macroglobulinemia. Dr Castillo gives an overview of the cardiac toxicity of ibrutinib, reporting atrial fibrillation as the most common cardiac adverse event (AEs) with a rate of 5-10%, and comments on risk factors for these AEs. Dr Castillo also outlines the management of patients with Waldenström’s macroglobulinemia who are receiving ibrutinib, highlighting the role of the cardiologist, and discusses the importance of minimising the risk of thromboembolic problems and educating patients on these risks. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Jorge Castillo, MD, has received research funds and/or consulting fees from Abbvie, Beigene, Janssen, Pharmacyclics, Roche and TG Therapeutics.